Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

News Focus

LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News AC Immune SA ACIU

Healthcare Biotechnology

AC Immune SA is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on precision medicine for neurodegenerative diseases. It designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small... see more

Add To Watchlist

Recent & Breaking News (NDAQ:ACIU)

AC Immune Announces Anti-Tau Monoclonal Antibody Entering Second Phase 2 Trial in Moderate Alzheimer’s Disease

GlobeNewswire February 20, 2019

AC Immune Makes Two Appointments to Executive Committee to Accelerate Product Development

GlobeNewswire February 7, 2019

AC Immune Announces Appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer

GlobeNewswire January 3, 2019

WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership

PR Newswire Asia December 19, 2018

AC Immune and WuXi Biologics to Establish an Exclusive Strategic Partnership

GlobeNewswire December 19, 2018

AC Immune and Lilly Announce License and Collaboration Agreement

GlobeNewswire December 12, 2018

Lilly and AC Immune Announce License and Collaboration Agreement

PR Newswire December 12, 2018

In Memoriam: Dr. Andreas Muhs CSO, Scientific Leader and Friend has Passed Away

GlobeNewswire December 7, 2018

AC Immune Awarded Third Follow-up Grant from The Michael J. Fox Foundation for First-in-Human Study of a Positron Emission Tomography (PET) Tracer for Parkinson's Disease

GlobeNewswire November 15, 2018

AC Immune Reports Third Quarter 2018 Financial Results and Corporate Update

GlobeNewswire November 13, 2018

AC Immune to Present at the Jefferies 2018 London Healthcare Conference

GlobeNewswire November 12, 2018

AC Immune Shares Insights from Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and Other Misfolded Proteins in AD and Neurodegenerative Diseases

GlobeNewswire November 9, 2018

AC Immune to Present at 2018 Society for Neurosciences Meeting

GlobeNewswire November 1, 2018

AC Immune to Host Key Opinion Leader Meeting on Abeta Oligomers in Alzheimer's Disease (AD) and the Involvement of Other Misfolded Proteins in AD and Neurodegenerative Diseases

GlobeNewswire November 1, 2018

AC Immune Partner Life Molecular Imaging Presents New Clinical Study Results for Tau PET-Tracer 18F-PI-2620

GlobeNewswire October 29, 2018

AC Immune SA: New Data Supporting Crenezumab as Potential Alzheimer's Therapy

GlobeNewswire October 29, 2018

AC Immune Selected to Present Progress on its Tau Morphomer Program in the Late Breaking News Session at CTAD Conference in Barcelona

GlobeNewswire October 25, 2018

AC Immune Announces Dr. Andreas Muhs, Chief Scientific Officer, to Take Medical Leave of Absence

GlobeNewswire October 22, 2018

Investor Expectations to Drive Momentum within Matthews International, AC Immune SA, Entercom Communications, Sunrun, Axcelis Technologies, and Advanced Disposal Services — Discovering Underlying Factors of Influence

GlobeNewswire October 17, 2018

Recent Analysis Shows STMicroelectronics N.V, Jagged Peak Energy, Inovalon, AC Immune SA, Repligen, and RealNetworks Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire August 22, 2018